Avadel Pharmaceuticals appoints Naseem Amin, M.D. to Board of Directors

AVADEL PHARMACEUTICALS PLC

Naseem Amin appointed effective May 17, 2024, as independent director.
Granted option to purchase 49,500 shares at $15.94, vesting over three years.
Amin is CEO of Orphalan SA with 30 years experience in biopharma and venture capital.
Board cites Amin's expertise to support commercial launch of LUMRYZ for narcolepsy.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Naseem Amin, MD

Director

AVADEL PHARMACEUTICALS PLC

Effective: 2024-05-17
Filed: May 21, 2024, 7:59 PM ET

On May 17, 2024, the Board of Directors (the “Board”) of Avadel Pharmaceuticals plc (the “Company”) appointed Naseem Amin, MD to the Board, effective as of May 17, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Naseem Amin, MD was appointed as Director at AVADEL PHARMACEUTICALS PLC.

Action: appointed
Role: Director

Exact text from the filing

On May 17, 2024, the Board of Directors (the “Board”) of Avadel Pharmaceuticals plc (the “Company”) appointed Naseem Amin, MD to the Board, effective as of May 17, 2024.

View on SEC.gov

Source: SEC EDGAR

accession 0001104659-24-063653

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.